

REMARKS

In accordance with the Revised Procedure for Preliminary Amendments published by the Office, Applicants have amended the specification of the present application by way of a Substitute Specification. Also in accordance with the Revised Procedure, Applicants have provided a clean version of the Substitute Specification and a marked-up version showing the changes made. Specific changes can be found on pages 1, 13, 20, 25, 26, 28 and 41 of the Marked-Up Substitute Specification. Applicants believe that no new matter enters by way of the Substitute Specification.

No fees are believed due for this Preliminary Amendment. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge any underpayment or credit overpayment of fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: 30 Nov 2005

By: James E. Butler
James E. Butler, Ph.D.
Registration No. 40931

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936